Study Complete
Sponsor ID
20050129
Evaluate the efficacy of AMG 706 to treat advanced gastrointestinal stromal tumors
Study Details
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
Protocol Summary
Primary Outcome Measures
The objective response rate as assessed by modified RECIST
Timeframe: Every 8 weeks
Secondary Outcome Measures
Duration of response, progression-free survival, time to response, overall survival, PK and safety profile
Timeframe: imaging, every 8 weeks; survival, every 6 months; PK, Days 1,15, 29, 43, 57, every 2 weeks in week 9 to 16, and every 4 weeks thereafter;
Locations
No locations found.